225 related articles for article (PubMed ID: 34115437)
1. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
[TBL] [Abstract][Full Text] [Related]
2. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
4. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Haase VH; Chertow GM; Block GA; Pergola PE; deGoma EM; Khawaja Z; Sharma A; Maroni BJ; McCullough PA
Nephrol Dial Transplant; 2019 Jan; 34(1):90-99. PubMed ID: 29672740
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
[TBL] [Abstract][Full Text] [Related]
7. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
[TBL] [Abstract][Full Text] [Related]
9. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
10. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
14. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
Sarnak MJ; Agarwal R; Boudville N; Chowdhury PCP; Eckardt KU; Gonzalez CR; Kooienga LA; Koury MJ; Ntoso KA; Luo W; Parfrey PS; Vargo DL; Winkelmayer WC; Zhang Z; Chertow GM
Nephrol Dial Transplant; 2023 Sep; 38(10):2358-2367. PubMed ID: 37096396
[TBL] [Abstract][Full Text] [Related]
15. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Akizawa T; Ueno M; Shiga T; Reusch M
Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
[TBL] [Abstract][Full Text] [Related]
17. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
[TBL] [Abstract][Full Text] [Related]
18. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
[TBL] [Abstract][Full Text] [Related]
19. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
20. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
